| Previous close | 249.85 |
| Open | 250.10 |
| Bid | 250.60 x 0 |
| Ask | 250.70 x 0 |
| Day's range | 249.60 - 251.50 |
| 52-week range | 213.00 - 277.90 |
| Volume | |
| Avg. volume | 181,514 |
| Market cap | 205.402B |
| Beta (5Y monthly) | 0.16 |
| PE ratio (TTM) | 17.51 |
| EPS (TTM) | 14.32 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 9.60 (3.84%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
GlobeNewswireRoche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection
The World Health Organization (WHO) has awarded Roche's human papillomavirus (HPV) test prequalification designations for use on the cobas 5800 System and for self-collected samples on the cobas 5800, 6800 and 8800 Systems. These designations build upon last June's WHO prequalification that included the cobas HPV test for use on the cobas 6800 and 8800 Systems.WHO prequalification enables low- and middle-income countries (LMICs) to use Roche HPV screening solutions, including self-collection, in
ZacksRoche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod
Roche (RHHBY) obtains approval for the subcutaneous formulation of relapsing multiple sclerosis drug Ocrevus in Europe. In addition, a review of the company's MAA for gene therapy, Elevidys, is also underway.
- GlobeNewswire
Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis
OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV) OCREVUS SC provides an additional treatment option without the need for IV facilities, expanding accessibility for patientsRoche is working closely with national health systems in Europe to ensure people with multiple sclerosis can access OCREVUS SC as quickly as possible Basel, 25 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today tha
